System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Christoph Wanner is an expert in Nephrology at University Hospital Würzburg (Germany). As of October 2026, ScienceLeadR ranks Christoph Wanner in the top 1% of experts worldwide for Renal Insufficiency, Lipid Metabolism Disorders and Kidney Transplantation. Christoph Wanner has authored 1,364 publications, the most recent in 2026, and is an investigator in 39 clinical trials, 2 of them ongoing. SLR score: 4,339 (community average: 125). How the SLR is computed.

LeadR Profile

Christoph Wanner University Hospital Würzburg Germany
4 339 ScienceLeadR Reputation 4339

Unlock

Register Login
Network Map

Nephrology

Subspecialties: Transplantation - Cardiology - Urology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1998 - 2026
Source: PubMed

University Hospital Würzburg

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1364

Citations

Citations: 102 565 1st author: 122 Last author: 235 Unique author: 29

Main journals

Nephrol Dial Transplant 219
Kidney Int 72
J Am Soc Nephrol 60
Clin Kidney J 49
Eur Heart J 43

Best Journals

N Engl J Med 22
Eur Heart J 13
Lancet 9

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Academic treatment optimization studies in oncology and internal medicine: a risk- and burden-adapted regulatory framework for the European Union.
PMID 42927209 — biomedical research, internal medicine, research, ethics committees, therapeutics, european union		Lancet Reg Health Eur20260
MEDA-PKD: a dynamic, real-time analytics platform for precision care in autosomal dominant polycystic kidney disease.
PMID 42901931 — kidney diseases, kidney, therapeutics, polycystic kidney diseases, polycystic kidney, autosomal dominant		NPJ Digit Med20260
A Microsimulation of Eligibility for Cardiorenal Combination Treatment and Potential Deaths Averted.
PMID 42853614 — diabetes mellitus, therapeutics, diabetes mellitus, type 2		J Am Soc Nephrol20260
Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
PMID 42842238 — kidney diseases, blood, cardiovascular diseases, blood pressure, kidney		JAMA Cardiol20260
Exploratory evidence of a slower eGFR decline in patients at high risk of CKD progression treated with PCSK9 inhibitors.
PMID 42791189 — kidney diseases, dyslipidemias, nephrology, kidney transplantation		J Nephrol20260

Clinical Studies 39

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 26
N/A 7
Phase 4 3
Phase 2 2
Phase 1 1

By status:

Completed 30
Active not recruiting 4
Terminated 3
Recruiting 2

By type:

Interventional 35
Observational 4

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 2
multicentric5to9 2
multicentricup10 27

Main Topics

Cohort/Consortium Investigators 33

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Called FINE REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
NCT05348733 — diabetes mellitus, kidney diseases, insulin, blood, pharmaceutical preparations, heart, blood pressure, kidney, drug-related side effects and adverse reactions, physicians, therapeutics, renal insufficiency, renal insufficiency, chronic, diabetes mellitus, type 2		N/AActive not recruiting2022
Fabry Disease in High risk Patients With Left Ventricular Hypertrophy Prevalence and Implementation of a Clinical Score
NCT04943991 — galactosidases, research design, genes, hypertrophy, left ventricular, heart diseases, genetic testing, blood, alpha-galactosidase, rare diseases, hypertrophy, lysosomal storage diseases, cardiomyopathy, hypertrophic, signs and symptoms, prevalence, diagnosis, therapeutics, cardiomyopathies, fabry disease		N/AActive not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS